drugset / Trial / NCT01887938
An Efficacy and Safety Study of HGT-1110 in Participants With Metachromatic Leukodystrophy
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to collect long-term safety data in participants with metachromatic leukodystrophy (MLD) who are receiving HGT-1110 and have participated in Study HGT-MLD-070 (NCT01510028) through Week 40.
Timeline
- Start
- 2013-05-23
- Primary completion
- 2026-02-13
- Completion
- 2026-02-13
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HGT-1110 | Protein / enzyme biologic | 10 mg | Other |
| Subject | HGT-1110 | Protein / enzyme biologic | 30 mg | Other |
| Subject | HGT-1110 | Protein / enzyme biologic | 100 mg | Other |
| Subject | HGT-1110 | Protein / enzyme biologic | 150 mg | Other |